Skip to main
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics Inc. is poised for a positive financial outlook, driven by promising clinical execution and improved investor sentiment, as evidenced by a significant target price increase. The company's lead product candidate, Veligrotug, has shown best-in-class potential in treating thyroid eye disease, demonstrating similar efficacy to Tepezza with enhanced patient quality of life measures and a favorable safety profile. Additionally, the introduction of VRDN-003, a subcutaneous offering, is expected to expand Viridian's market share and treatment accessibility, further solidifying its competitive positioning in the thyroid eye disease space.

Bears say

The analysis suggests a negative outlook on Viridian Therapeutics's stock due to several potential risks that could significantly impact its valuation. A delayed launch of Veligrotug could result in a valuation decrease of approximately $4 per share, while failure in key studies could lead to a substantial drop of around $14 per share, indicating a potential 30% downside risk. Furthermore, challenges related to intellectual property protection and competition from well-capitalized peers, combined with potential manufacturing and regulatory setbacks, exacerbate concerns about the company's ability to successfully execute its commercialization strategy.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.